Form 4: Dianthus Therapeutics Director Receives Stock Option Grant

Director Anne McGeorge was granted 6,090 stock options in Dianthus Therapeutics, Inc. as part of a standard equity compensation award.

Summary

• Director Anne McGeorge received a grant of 6,090 stock options for Dianthus Therapeutics, Inc. (DNTH) common stock.
• The options have an exercise price of $89.63 per share.
• The grant date for these options is May 21, 2026.
• The options are set to expire on May 21, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in minor potential future dilution for existing shareholders upon exercise of the options.

Risks

• The value of the options is dependent on the future market performance of the company's common stock.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or the Issuer's 2027 Annual Meeting of Stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard practices for mid-cap biotechnology firms.
• The grant size is typical for a non-employee director compensation package in this industry.

Stakeholder Impact

• Minor dilution impact on existing shareholders.

Next Steps

• Vesting of options on the earlier of May 21, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Dianthus Therapeutics, DNTH, Form 4, Insider Trading, Stock Options, Director Compensation